- Category: HCV Treatment
- Published on Sunday, 10 January 2016 00:00
- Written by Michael Carter
Treatment using direct-acting antiviral agents (DAAs) could have a major impact on the hepatitis C virus (HCV) epidemic in the U.S., according to a model published in the November 30 online edition of Clinical Infectious Diseases. A 4-fold increase in treatment rates could prevent over a quarter of a million HCV-related deaths by 2040, and prevalence could be reduced by 90% with the scale up of screening efforts, especially targeting people who inject drugs (PWID). But the investigators caution that elimination of the epidemic with DAAs would require near-universal testing and a 20% annual treatment rate.